Stock DNA
Pharmaceuticals & Biotechnology
CNY 23,150 Million (Large Cap)
12.00
NA
8.32%
-0.73
14.13%
1.71
Revenue and Profits:
Net Sales:
1,198 Million
(Quarterly Results - Jun 2025)
Net Profit:
284 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.26%
0%
7.26%
6 Months
-0.26%
0%
-0.26%
1 Year
-7.89%
0%
-7.89%
2 Years
-13.68%
0%
-13.68%
3 Years
-13.73%
0%
-13.73%
4 Years
48.45%
0%
48.45%
5 Years
23.44%
0%
23.44%
Hubei Jumpcan Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.31%
EBIT Growth (5y)
4.74%
EBIT to Interest (avg)
81.87
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.59
Tax Ratio
14.86%
Dividend Payout Ratio
75.53%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
56.77%
ROE (avg)
17.31%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.71
EV to EBIT
7.05
EV to EBITDA
6.05
EV to Capital Employed
3.63
EV to Sales
2.02
PEG Ratio
NA
Dividend Yield
8.32%
ROCE (Latest)
51.43%
ROE (Latest)
14.13%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,197.80
1,497.00
-19.99%
Operating Profit (PBDIT) excl Other Income
321.70
505.60
-36.37%
Interest
3.50
3.50
Exceptional Items
-44.50
12.00
-470.83%
Consolidate Net Profit
284.00
441.30
-35.64%
Operating Profit Margin (Excl OI)
202.80%
285.10%
-8.23%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -19.99% vs -31.02% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -35.64% vs -29.89% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
7,882.50
9,508.30
-17.10%
Operating Profit (PBDIT) excl Other Income
2,734.40
3,188.50
-14.24%
Interest
28.40
18.60
52.69%
Exceptional Items
98.90
14.60
577.40%
Consolidate Net Profit
2,536.70
2,827.10
-10.27%
Operating Profit Margin (Excl OI)
307.70%
303.40%
0.43%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -17.10% vs 7.35% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -10.27% vs 30.18% in Dec 2023
About Hubei Jumpcan Pharmaceutical Co., Ltd. 
Hubei Jumpcan Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






